Structural basis for isotype selectivity of the human retinoic acid nuclear receptor.

The human retinoic acid receptor (hRAR) belongs to the family of nuclear receptors that regulate transcription in a ligand-dependent way. The isotypes RARalpha,beta and gamma are distinct pharmacological targets for retinoids that are involved in the treatment of various skin diseases and cancers, in particular breast cancer and acute promyelocytic leukemia. Therefore, synthetic retinoids have been developed aiming at isotype selectivity and reduced side-effects. We report the crystal structures of three complexes of the hRARgamma ligand-binding domain (LBD) bound to agonist retinoids that possess selectivity either for RARgamma (BMS184394) or for RARbeta/gamma (CD564), or that are potent for all RAR-isotypes (panagonist BMS181156). The high resolution data (1.3-1. 5 A) provide a description at the atomic level of the ligand pocket revealing the molecular determinants for the different degrees of ligand selectivity. The comparison of the complexes of the chemically closely related retinoids BMS184394 and CD564 shows that the side-chain of Met272 adopts different conformations depending on the presence of a hydrogen bond between its sulfur atom and the ligand. This accounts for their different isotype selectivity. On the other hand, the difference between the pan- and the RARbeta, gamma-selective agonist is probably due to a steric discrimination at the level of the 2-naphthoic acid moiety of CD564. Based on this study, we propose a model for a complex with the RARgamma-specific agonist CD666 that shows the possible applications for structure-based drug design of RAR isotype-selective retinoids.

[1]  F. Allen,et al.  The Cambridge Crystallographic Data Centre: computer-based search, retrieval, analysis and display of information , 1979 .

[2]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[3]  Y. Hashimoto,et al.  Chalcone carboxylic acids. Potent differentiation inducers of human promyelocytic cells HL-60. , 1985, Chemical & pharmaceutical bulletin.

[4]  R. Read.  Improved Fourier Coefficients for Maps Using Phases from Partial Structures with Errors , 1986 .

[5]  E. Hodak,et al.  Adverse Effects of Retinoids , 1988, Medical toxicology and adverse drug experience.

[6]  Y. Hashimoto,et al.  Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity. , 1988, Journal of medicinal chemistry.

[7]  Y. Hashimoto,et al.  Retinobenzoic acids. 2. Structure-activity relationships of chalcone-4-carboxylic acids and flavone-4'-carboxylic acids. , 1989, Journal of medicinal chemistry.

[8]  R. Huber,et al.  Accurate Bond and Angle Parameters for X-ray Protein Structure Refinement , 1991 .

[9]  M. Pfahl,et al.  6'-substituted naphthalene-2-carboxylic acid analogs, a new class of retinoic acid receptor subtype-specific ligands. , 1991, Biochemical and biophysical research communications.

[10]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[11]  B. Shroot,et al.  Selective high affinity retinoic acid receptor alpha or beta-gamma ligands. , 1991, Molecular pharmacology.

[12]  B. Shroot,et al.  Selective synthetic ligands for human nuclear retinoic acid receptors. , 1992, Skin pharmacology : the official journal of the Skin Pharmacology Society.

[13]  J. Lehmann,et al.  Retinoids selective for retinoid X receptor response pathways. , 1992, Science.

[14]  A. Brunger.  Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. , 1992 .

[15]  B. Shroot,et al.  Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor gamma. , 1992, Biochemical and biophysical research communications.

[16]  J. Pike,et al.  Transactivation properties of retinoic acid and retinoid X receptors in mammalian cells and yeast. Correlation with hormone binding and effects of metabolism. , 1993, The Journal of biological chemistry.

[17]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[18]  S V Evans,et al.  SETOR: hardware-lighted three-dimensional solid model representations of macromolecules. , 1993, Journal of molecular graphics.

[19]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[20]  K. R. Ely,et al.  Correlation of retinoid binding affinity to retinoic acid receptor alpha with retinoid inhibition of growth of estrogen receptor-positive MCF-7 mammary carcinoma cells. , 1995, Cancer research.

[21]  H. Gronemeyer,et al.  Transcription factors 3: nuclear receptors. , 1995, Protein profile.

[22]  J. Starrett,et al.  Role of retinoic acid receptor gamma in the Rhino mouse and rabbit irritation models of retinoid activity. , 1995, Skin pharmacology : the official journal of the Skin Pharmacology Society.

[23]  Philippe Kastner,et al.  Nonsteroid nuclear receptors: What Are genetic studies telling us about their role in real life? , 1995, Cell.

[24]  B. Shroot,et al.  Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes. , 1995, Journal of medicinal chemistry.

[25]  Jean-Paul Renaud,et al.  Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid , 1995, Nature.

[26]  V. Seewaldt,et al.  Expression of retinoic acid receptor beta mediates retinoic acid-induced growth arrest and apoptosis in breast cancer cells. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[27]  William Bourguet,et al.  A canonical structure for the ligand-binding domain of nuclear receptors , 1996, Nature Structural Biology.

[28]  P. Pelicci,et al.  The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. , 1996, Blood.

[29]  V. Thomazy,et al.  Retinoid-induced epiphyseal plate closure in guinea pigs. , 1996, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[30]  R. Lotan.  Retinoids in cancer chemoprevention , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  J. Thornton,et al.  Deviations from planarity of the peptide bond in peptides and proteins. , 1996, Journal of molecular biology.

[32]  P. Chambon.  A decade of molecular biology of retinoic acid receptors , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  K. Rothman,et al.  Teratogenicity of high vitamin A intake. , 1995, The New England journal of medicine.

[34]  J. Voorhees,et al.  Molecular mechanisms of retinoid actions in skin , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  R. Buchsbaum,et al.  RARβ2-Mediated Growth Inhibition in HeLa Cells , 1996 .

[36]  J. Starrett,et al.  Retinoic acid receptor β,γ-selective ligands : Synthesis and biological activity of 6-substituted 2-naphthoic acid retinoids , 1996 .

[37]  S. Friant,et al.  Negative regulation of two hyperproliferative keratinocyte differentiation markers by a retinoic acid receptor-specific retinoid: insight into the mechanism of retinoid action in psoriasis. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[38]  M. Dawson,et al.  Receptor-selective retinoid agonists and teratogenic activity. , 1996, Drug metabolism reviews.

[39]  G. Sheldrick,et al.  SHELXL: high-resolution refinement. , 1997, Methods in enzymology.

[40]  T. Barbui,et al.  Molecular Remission in PML/RARα-Positive Acute Promyelocytic Leukemia by Combined All-trans Retinoic Acid and Idarubicin (AIDA) Therapy , 1997 .

[41]  P. Chambon,et al.  Purification of the Human RARγ Ligand-Binding Domain and Crystallization of Its Complex with All-transRetinoic Acid , 1997 .

[42]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[43]  M. Widschwendter,et al.  Activity of retinoic acid receptor‐γ selectively binding retinoids alone and in combination with interferon‐γ in breast cancer cell lines , 1997 .

[44]  M. Sporn,et al.  Recent advances in chemoprevention of cancer. , 1997, Science.

[45]  G. Hortobagyi,et al.  Progressive decrease in nuclear retinoic acid receptor beta messenger RNA level during breast carcinogenesis. , 1997, Cancer research.

[46]  M. Sundaralingam,et al.  C-H...O hydrogen bonding in biology. , 1997, Trends in biochemical sciences.

[47]  L. Fisher,et al.  Pathogenesis of vitamin (A and D)-induced premature growth-plate closure in calves. , 1997, Bone.

[48]  T. Eberlein,et al.  Specific Activation of Retinoic Acid Receptors (RARs) and Retinoid X Receptors Reveals a Unique Role for RARγ in Induction of Differentiation and Apoptosis of S91 Melanoma Cells* , 1997, The Journal of Biological Chemistry.

[49]  H. Gronemeyer,et al.  The nuclear receptor ligand-binding domain: structure and function. , 1998, Current opinion in cell biology.

[50]  D. Moras,et al.  A eucentric goniometer head sliding on an extended removable arc modified for use in cryocrystallography , 1998 .

[51]  P. Chambon,et al.  Conformational adaptation of agonists to the human nuclear receptor RARγ , 1998, Nature Structural Biology.

[52]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[53]  Chris Sander,et al.  Who checks the checkers? Four validation tools applied to eight atomic resolution structures. EU 3-D Validation Network. , 1998, Journal of molecular biology.

[54]  J. Voorhees,et al.  Ultraviolet irradiation of human skin causes functional vitamin A deficiency, preventable by all-trans retinoic acid pre-treatment , 1999, Nature Medicine.

[55]  P Chambon,et al.  Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists. , 1999, Chemistry & biology.

[56]  J. Kurie.  The biologic basis for the use of retinoids in cancer prevention and treatment. , 1999, Current opinion in oncology.

[57]  J. Voorhees,et al.  Erratum: Ultraviolet irradiation of human skin causes functional vitamin A deficiency, preventable by all-trans retinoic acid pre-treatment (Nature Medicine (1999) 5 (418-422)) , 1999 .

[58]  D. Moras,et al.  Structural role of a detergent molecule in retinoic acid nuclear receptor crystals. , 2000, Acta crystallographica. Section D, Biological crystallography.

[59]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[60]  P. Chambon,et al.  Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. , 2000, Molecular cell.

[61]  D. Moras,et al.  Enantiomer discrimination illustrated by high-resolution crystal structures of the human nuclear receptor hRARgamma. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[62]  P. Chambon,et al.  Crystal structure of the human RXRα ligand‐binding domain bound to its natural ligand: 9‐cis retinoic acid , 2000 .